ClinicalTrialsFinder
RecruitingPhase 4NCT06585241

A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations

A Phase 3b/4, Open-label Study to Assess the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations

Sponsor

ModernaTX, Inc.

Enrollment

1,144 participants

Start Date

Sep 9, 2024

Study Type

INTERVENTIONAL

Conditions

SARS CoV-2

Summary

The purpose of this study is to investigate the immunogenicity and safety of mRNA COVID-19 variant-containing vaccine formulations against the vaccine-matched variants and newly emerged variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Eligibility

Min Age: 6 Months

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called mRNA-1273 Variant-containing Formulation for people with sars cov-2. The study is currently recruiting participants at 6 locations. People eligible for this study include aged 6 Months and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALmRNA-1273 Variant-containing Formulation

Sterile liquid for injection

Locations(6)

CenExel

Atlanta, Georgia, United States

CenExel

Decatur, Georgia, United States

Velocity Clinical Research

Baton Rouge, Louisiana, United States

Velocity Clinical Research

Gulfport, Mississippi, United States

Velocity Clinical Research

Omaha, Nebraska, United States

Richard Bennett - Clinical Research Partners

Richmond, Virginia, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06585241

Related Trials

A Study of Secutrelvir in Participants With Coronavirus Disease 2019 (COVID-19) Who Are at High Risk for Progression to Severe Disease

NCT07743580

Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease

NCT072244901 location

Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm in Patients With Acute Respiratory Infection Caused by SARS-Cov-2, Influenza A, Influenza B and Respiratory Syncytial Virus (RSV)

NCT066843793 locations

Effect of COV2 Vaccine Formulation on the Ability to Generate Antibodies Against Coronavirus That Causes COVID-19

NCT074165391 location

COVID-19 - Study of the Kinetics of the Immune Response During the Intensive Care Unit Stay in Adult Patients Infected With SARS-CoV-2: Multicentric Non Interventional Study

NCT043924018 locations